AbCellera Biologics Inc. (NASDAQ:ABCL) Expected to Earn FY2026 Earnings of ($0.67) Per Share

AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Investment analysts at Bloom Burton issued their FY2026 earnings estimates for shares of AbCellera Biologics in a research note issued to investors on Thursday, May 9th. Bloom Burton analyst D. Martin anticipates that the company will earn ($0.67) per share for the year. The consensus estimate for AbCellera Biologics' current full-year earnings is ($0.66) per share.

A number of other equities analysts have also recently issued reports on the company. Stifel Nicolaus lowered their target price on AbCellera Biologics from $21.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 21st. Benchmark upgraded AbCellera Biologics from a "hold" rating to a "buy" rating and set a $9.00 target price for the company in a report on Thursday, February 22nd. Finally, KeyCorp decreased their price objective on AbCellera Biologics from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $16.17.

AbCellera Biologics Price Performance

ABCL stock traded down $0.12 during trading hours on Friday, reaching $3.83. 1,191,575 shares of the stock were exchanged, compared to its average volume of 1,390,794. The firm's 50-day moving average is $4.36 and its 200-day moving average is $4.78. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -7.46 and a beta of 0.42. AbCellera Biologics has a 12 month low of $3.62 and a 12 month high of $8.05.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. AbCellera Biologics had a negative net margin of 384.99% and a negative return on equity of 12.36%. The business had revenue of $9.95 million during the quarter, compared to analysts' expectations of $10.73 million. During the same quarter in the prior year, the company earned ($0.14) EPS. The firm's quarterly revenue was down 18.4% on a year-over-year basis.

Institutional Investors Weigh In On AbCellera Biologics

Hedge funds have recently bought and sold shares of the company. Intellectus Partners LLC lifted its position in AbCellera Biologics by 1.2% during the fourth quarter. Intellectus Partners LLC now owns 887,283 shares of the company's stock worth $5,066,000 after acquiring an additional 10,650 shares during the last quarter. Schonfeld Strategic Advisors LLC lifted its position in AbCellera Biologics by 143.1% during the third quarter. Schonfeld Strategic Advisors LLC now owns 358,400 shares of the company's stock worth $1,649,000 after acquiring an additional 211,000 shares during the last quarter. Dark Forest Capital Management LP lifted its position in AbCellera Biologics by 199.6% during the third quarter. Dark Forest Capital Management LP now owns 278,618 shares of the company's stock worth $1,282,000 after acquiring an additional 185,606 shares during the last quarter. Trexquant Investment LP lifted its position in AbCellera Biologics by 458.5% during the third quarter. Trexquant Investment LP now owns 272,158 shares of the company's stock worth $1,252,000 after acquiring an additional 223,430 shares during the last quarter. Finally, Graham Capital Management L.P. lifted its position in AbCellera Biologics by 149.4% during the third quarter. Graham Capital Management L.P. now owns 180,389 shares of the company's stock worth $830,000 after acquiring an additional 108,060 shares during the last quarter. 61.42% of the stock is currently owned by institutional investors and hedge funds.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.